Trials are currently underway testing IL6 and PD-1 pathway inhibitor combinations for improved anti-tumor efficacy and irAEs (NCT03999749, NCT04258150) (Doms et al, 2020; Stroud et al, 2019). Here, IL6 is linked to neoplasm.